1. Home
  2. CUE vs TPCS Comparison

CUE vs TPCS Comparison

Compare CUE & TPCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CUE
  • TPCS
  • Stock Information
  • Founded
  • CUE 2014
  • TPCS 1956
  • Country
  • CUE United States
  • TPCS United States
  • Employees
  • CUE N/A
  • TPCS N/A
  • Industry
  • CUE Biotechnology: Pharmaceutical Preparations
  • TPCS Metal Fabrications
  • Sector
  • CUE Health Care
  • TPCS Industrials
  • Exchange
  • CUE Nasdaq
  • TPCS Nasdaq
  • Market Cap
  • CUE 59.5M
  • TPCS 51.4M
  • IPO Year
  • CUE 2018
  • TPCS N/A
  • Fundamental
  • Price
  • CUE $0.74
  • TPCS $5.35
  • Analyst Decision
  • CUE Strong Buy
  • TPCS
  • Analyst Count
  • CUE 2
  • TPCS 0
  • Target Price
  • CUE $3.00
  • TPCS N/A
  • AVG Volume (30 Days)
  • CUE 116.9K
  • TPCS 62.3K
  • Earning Date
  • CUE 08-12-2025
  • TPCS 08-21-2025
  • Dividend Yield
  • CUE N/A
  • TPCS N/A
  • EPS Growth
  • CUE N/A
  • TPCS N/A
  • EPS
  • CUE N/A
  • TPCS N/A
  • Revenue
  • CUE $8,286,000.00
  • TPCS $33,424,000.00
  • Revenue This Year
  • CUE N/A
  • TPCS N/A
  • Revenue Next Year
  • CUE $10.19
  • TPCS N/A
  • P/E Ratio
  • CUE N/A
  • TPCS N/A
  • Revenue Growth
  • CUE N/A
  • TPCS 3.78
  • 52 Week Low
  • CUE $0.45
  • TPCS $2.05
  • 52 Week High
  • CUE $1.99
  • TPCS $6.25
  • Technical
  • Relative Strength Index (RSI)
  • CUE 38.09
  • TPCS 53.42
  • Support Level
  • CUE $0.77
  • TPCS $5.10
  • Resistance Level
  • CUE $0.79
  • TPCS $5.50
  • Average True Range (ATR)
  • CUE 0.04
  • TPCS 0.29
  • MACD
  • CUE -0.01
  • TPCS -0.05
  • Stochastic Oscillator
  • CUE 12.87
  • TPCS 39.87

About CUE Cue Biopharma Inc.

Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.

About TPCS TechPrecision Corporation Common stock

Techprecision Corp manufactures metal fabricated and machined precision components and systems. It offers a full range of services required to transform raw materials into precision finished products. The company's products are used in markets including defense, aerospace, nuclear, medical, and precision industries. All of its operations and customers are located in the United States. The company have two wholly owned subsidiaries that are each reportable segments: Ranor and Stadco. Each reportable segment focuses on the manufacture and assembly of specific components. It derives maximum revenue from Ranor segment.

Share on Social Networks: